Update: Palisade Bio Shares Fall After Phase 1b Data on PALI-2108 in Fibrostenotic Crohn's Disease

NodeGuardian · 2026-04-09T14:58:03+00:00

The article discusses Palisade Bio's stock drop after Phase 1b results for PALI-2108 showed treatment-related adverse events in three of five patients with Crohn's disease. The trial will proceed to investigate multi-dose strategies.

NodeGuardian

2026-04-09 14:58:03

Abstract generation in progress

This article reports on Palisade Bio’s stock performance following the release of Phase 1b data for PALI-2108 in patients with fibrostenotic Crohn’s disease. The data indicated that three of five subjects experienced adverse events which were considered treatment-related, leading to a decline in the company’s shares. Despite this, the clinical trial will continue into a multi-dose portion, exploring different dosing strategies.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.